Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
L to R: Taranpreet Lamba, VP & Head, Portfolio Planning & IP Litigation, Sun Pharma; Sudarshan Jain, Secretary General, IPA India; Robert Stanley, Global Head Intellectual Property & Legal Innovation, Head Legal, International ad interim, Novartis; Leena Menghaney, IP Advisor & Head, MSF, South Asia; Christoph Koenen, Global Head of Clinical Development & Operations, Bayer; & Pravin Anand, Managing Partner, Anand and Anand • Source: BioAsia
A panel discussion on intellectual property rights in India was marked by diverging positions and counter arguments on certain key provisions including pre-grant oppositions and restrictions on patent-eligible subject matter as covered in Section 3(d) of the country’s patent regulations.
Key Takeaways
High-profile panel discusses on-the-ground realities of India’s IPR landscape and 'dramatic' improvements.
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.